Analyst Price Target is $9.17
▲ +286.78% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cognition Therapeutics in the last 3 months. The average price target is $9.17, with a high forecast of $14.00 and a low forecast of $5.00. The average price target represents a 286.78% upside from the last price of $2.37.
Current Consensus is
Buy
The current consensus among 6 investment analysts is to buy stock in Cognition Therapeutics. This Buy consensus rating has held steady for over two years.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Read More